BioSpace News Archive

Science 37® Holdings, Inc., the industry-leading Metasite™, announced the company will be participating in the upcoming 5th Annual Evercore ISI HealthCONx Conference.

Aura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, announced the launch of an underwritten public offering of its common stock.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the virtual JMP Securities Hematology and Oncology Summit being held from December 6-7, 2022.

Aziyo Biologics, Inc., a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, announced that it has commenced an underwritten public offering, subject to market and other conditions, of shares of its common stock.

Conformis, Inc. announced that it received a letter from the Listing Qualifications Department of The NASDAQ Stock Market on Nov 25, 2022 notifying Conformis that, based on the closing bid price of Conformis’ common stock having been $1.00 per share or greater on each of the trading days from Nov 10, 2022 to Nov 23, 2022, Conformis has regained compliance with Nasdaq Listing Rule 5550 and the minimum bid price deficiency matter previously disclosed by Conformis is now closed.

SQZ Biotechnologies (NYSE: SQZ) today announced the strategic prioritization of its clinical portfolio to concentrate on the development of its second-generation enhanced Antigen Presenting Cells (eAPC) cell therapy program, focused on HPV16 positive recurrent, locally advanced, or metastatic solid tumors.

Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced that it has commenced an underwritten public offering of $250 million of shares of its common stock.

TC BioPharm PLC announced the closing of its previously announced private placement for the issuance and sale of 1,470,000 American Depositary Shares, Series A warrants to purchase up to an aggregate of 1,470,000 ADSs and Series B warrants to purchase up to an aggregate of 1,470,000 ADSs at a purchase price of $5.00 per ADS and associated warrants.

Ferring Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approved REBYOTA® (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on November 30, 2022.